Hyperbaric Oxygen Therapy in Acute Ischemic Stroke Ischemic Stroke Recovery (Pro00061930)

Description

This study will critically examine the feasibility, safety and efficacy of HBOT during inpatient rehabilitation (IPR) after acute ischemic stroke measured by non-disruption of 3 hours of daily therapy, frequency of neurological deterioration or complications (seizure, hemorrhage, brain edema), and functional communication, activities of daily living (ADLs) and mobility.

Conditions

Acute Ischemic Stroke

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will critically examine the feasibility, safety and efficacy of HBOT during inpatient rehabilitation (IPR) after acute ischemic stroke measured by non-disruption of 3 hours of daily therapy, frequency of neurological deterioration or complications (seizure, hemorrhage, brain edema), and functional communication, activities of daily living (ADLs) and mobility.

Hyperbaric Oxygen Therapy in Acute Ischemic Stroke Recovery

Hyperbaric Oxygen Therapy in Acute Ischemic Stroke Ischemic Stroke Recovery (Pro00061930)

Condition
Acute Ischemic Stroke
Intervention / Treatment

-

Contacts and Locations

New Orleans

Touro Infirmary New Orleans, New Orleans, Louisiana, United States, 70112

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 18 years and above
  • * Ischemic stroke proven on neuroimaging
  • * Within 7-30 days post-stroke on day 1 of treatment
  • * Admitted to Touro Inpatient Rehab Facility
  • * Pre-stroke modified Rankin Scale Score \>2
  • * Parenchymal hemorrhagic transformation (PH1 or PH2)
  • * Receptive aphasia such that recommendations for preventative measures to mitigate barotrauma cannot be followed
  • * History of recurrent and unprovoked seizures requiring a change in management in the last 3 months to control seizures
  • * Pulmonary disease requiring supplemental oxygen or daily respiratory medication management (metered dose inhalers, nebulized treatment or steroids)

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

LCMC Health,

Study Record Dates

2026-12-31